Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

New England Journal of Medicine - Tập 364 Số 26 - Trang 2507-2516 - 2011
Paul B. Chapman1, Axel Hauschild2, Caroline Robert3, John B.A.G. Haanen4, Paolo A. Ascierto5, James Larkin6, Reinhard Dummer7, Claus Garbe8, Alessandro Testori9, Michele Maio10, David Hogg11, Paul Lorigan12, Célèste Lebbe13, Thomas Jouary14, Dirk Schadendorf15, Antoni Ribas16, Steven O’Day17, Jeffrey A. Sosman18, John M. Kirkwood19, Alexander M.M. Eggermont3, Brigitte Dréno20, K. B. Nolop21, Jiang Li22, B. Nelson23, Jean‐Jacques Grob23, Richard J. Lee22, Keith T. Flaherty24, Grant A. McArthur25
1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York
2University of Kiel, Kiel
3Institut Gustave Roussy
4Netherlands Cancer Institute, Amsterdam
5Istituto Nazionale Tumori Fondazione Pascale, Naples
6Department of Medical Oncology, Royal Marsden Hospital, London
7Department of Dermatology, University of Zurich, Zurich, Switzerland
8University of Tübingen, Tübingen
9Istituto Europeo di Oncologia, Milan
10Istituto Toscano Tumori, Florence
11Princess Margaret Hospital and University Health Network, Toronto
12University of Manchester, Manchester, United Kingdom
13Service de dermatologie, hôpital Saint Louis
14Saint Andre Hospital, Bordeaux
15University Hospital Essen, Essen
16Department of Medicine, David Geffen School of Medicine at UCLA
17Angeles Clinic and Research Institute
18Department of Medicine, Vanderbilt University School of Medicine, Nashville
19Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh
20Department of Dermatology, Nantes University Hospital, Nantes
21Plexxikon, Berkeley, CA
22Hoffmann–La Roche, Nutley NJ
23Genentech, San Francisco
24Department of Medicine, Massachusetts General Hospital, Boston
25Peter MacCallum Cancer Center, Melbourne, VIC, Australia

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1200/JCO.2009.23.4799

10.3322/caac.20073

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase no. 10. Lyon, France: International Agency for Research on Cancer, 2010. (http://globocan.iarc.fr.)

Chapman PB, 1999, J Clin Oncol, 17, 2745, 10.1200/JCO.1999.17.9.2745

Middleton MR, 2000, J Clin Oncol, 18, 158, 10.1200/JCO.2000.18.1.158

10.1200/JCO.2004.04.165

10.1200/JCO.2006.06.0483

10.1056/NEJMoa1003466

Wolchok JD, 2011, J Clin Oncol, 29, LBA5, 10.1200/jco.2011.29.18_suppl.lba5

10.1038/nature00766

10.1056/NEJMoa050092

10.1038/nature09454

10.1073/pnas.0711741105

10.1073/pnas.1008990107

10.1056/NEJMoa1002011

Ribas A, 2011, J Clin Oncol, 29, 8509, 10.1200/jco.2011.29.15_suppl.8509

10.1016/S0140-6736(02)08594-X

10.1200/JCO.2010.32.4327

10.1016/j.ccr.2010.10.029

Kumar R, 2003, Clin Cancer Res, 9, 3362

10.1111/j.1365-4632.2010.04822.x

10.1016/j.jaad.2008.10.043

10.1038/nature08902

10.1038/nature08833

10.1016/j.cell.2009.12.040

10.1038/nature09627

10.1038/nature09626

10.1016/j.ccr.2010.11.023

Thông tin
Thông tin xuất bản

New England Journal of Medicine

Tập 364 Số 26

2507-2516

Thông tin tác giả